Psychemedics Corporation
Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy… Read more
Psychemedics Corporation (PMD) - Net Assets
Latest net assets as of September 2024: $5.45 Million USD
Based on the latest financial reports, Psychemedics Corporation (PMD) has net assets worth $5.45 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.84 Million) and total liabilities ($4.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.45 Million |
| % of Total Assets | 55.37% |
| Annual Growth Rate | 6.07% |
| 5-Year Change | -60.33% |
| 10-Year Change | -48.02% |
| Growth Volatility | 67.45 |
Psychemedics Corporation - Net Assets Trend (1987–2023)
This chart illustrates how Psychemedics Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Psychemedics Corporation (1987–2023)
The table below shows the annual net assets of Psychemedics Corporation from 1987 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $6.67 Million | -38.06% |
| 2022-12-31 | $10.77 Million | -12.02% |
| 2021-12-31 | $12.24 Million | -2.15% |
| 2020-12-31 | $12.51 Million | -25.61% |
| 2019-12-31 | $16.82 Million | -10.28% |
| 2018-12-31 | $18.75 Million | +0.68% |
| 2017-12-31 | $18.62 Million | +19.31% |
| 2016-12-31 | $15.61 Million | +33.70% |
| 2015-12-31 | $11.67 Million | -9.06% |
| 2014-12-31 | $12.84 Million | +4.56% |
| 2013-12-31 | $12.28 Million | +9.40% |
| 2012-12-31 | $11.22 Million | +1.70% |
| 2011-12-31 | $11.03 Million | +13.20% |
| 2010-12-31 | $9.75 Million | +4.88% |
| 2009-12-31 | $9.29 Million | -11.98% |
| 2008-12-31 | $10.56 Million | -23.91% |
| 2007-12-31 | $13.88 Million | +20.64% |
| 2006-12-31 | $11.50 Million | +29.33% |
| 2005-12-31 | $8.89 Million | +42.68% |
| 2004-12-31 | $6.23 Million | +21.98% |
| 2003-12-31 | $5.11 Million | -19.43% |
| 2002-12-31 | $6.34 Million | -6.32% |
| 2001-12-31 | $6.77 Million | -22.39% |
| 2000-12-31 | $8.73 Million | -26.05% |
| 1999-12-31 | $11.80 Million | -25.79% |
| 1998-12-31 | $15.90 Million | -4.79% |
| 1997-12-31 | $16.70 Million | +16.78% |
| 1996-12-31 | $14.30 Million | +50.53% |
| 1995-12-31 | $9.50 Million | -1.04% |
| 1994-12-31 | $9.60 Million | +174.29% |
| 1993-12-31 | $3.50 Million | +34.62% |
| 1992-12-31 | $2.60 Million | -3.70% |
| 1991-12-31 | $2.70 Million | +350.00% |
| 1990-12-31 | $600.00K | -14.29% |
| 1989-12-31 | $700.00K | -12.50% |
| 1987-12-31 | $800.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Psychemedics Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1447300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $32.00K | 0.48% |
| Other Comprehensive Income | $-1.63 Million | -24.49% |
| Other Components | $25.05 Million | 375.40% |
| Total Equity | $6.67 Million | 100.00% |
Psychemedics Corporation Competitors by Market Cap
The table below lists competitors of Psychemedics Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Spinnova Oy
HE:SPINN
|
$11.50 Million |
|
Cirralto Limited
PINK:CROTF
|
$11.50 Million |
|
PT Salim Ivomas Pratama Tbk
STU:2IR
|
$11.50 Million |
|
Ktop Reit
KO:145270
|
$11.51 Million |
|
GRITEE Inc
KQ:204020
|
$11.49 Million |
|
Tartisan Nickel Corp
OTCQX:TTSRF
|
$11.49 Million |
|
MHC JSC
VN:MHC
|
$11.49 Million |
|
Urbi Desarrollos Urbanos S.A.B. de C.V
MX:URBI
|
$11.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Psychemedics Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 10,771,000 to 6,672,000, a change of -4,099,000 (-38.1%).
- Net loss of 4,154,000 reduced equity.
- Dividend payments of 799,000 reduced retained earnings.
- Share repurchases of 54,000 reduced equity.
- Other factors increased equity by 908,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.15 Million | -62.26% |
| Dividends Paid | $799.00K | -11.98% |
| Share Repurchases | $54.00K | -0.81% |
| Other Changes | $908.00K | +13.61% |
| Total Change | $- | -38.06% |
Book Value vs Market Value Analysis
This analysis compares Psychemedics Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.30x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.45x to 2.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1987-12-31 | $0.49 | $2.67 | x |
| 1989-12-31 | $0.27 | $2.67 | x |
| 1990-12-31 | $0.20 | $2.67 | x |
| 1991-12-31 | $0.71 | $2.67 | x |
| 1992-12-31 | $0.67 | $2.67 | x |
| 1993-12-31 | $0.90 | $2.67 | x |
| 1994-12-31 | $1.91 | $2.67 | x |
| 1995-12-31 | $1.62 | $2.67 | x |
| 1996-12-31 | $2.58 | $2.67 | x |
| 1997-12-31 | $2.96 | $2.67 | x |
| 1998-12-31 | $2.82 | $2.67 | x |
| 1999-12-31 | $2.14 | $2.67 | x |
| 2000-12-31 | $1.62 | $2.67 | x |
| 2001-12-31 | $1.27 | $2.67 | x |
| 2002-12-31 | $1.20 | $2.67 | x |
| 2003-12-31 | $0.98 | $2.67 | x |
| 2004-12-31 | $1.21 | $2.67 | x |
| 2005-12-31 | $1.72 | $2.67 | x |
| 2006-12-31 | $2.20 | $2.67 | x |
| 2007-12-31 | $2.62 | $2.67 | x |
| 2008-12-31 | $2.01 | $2.67 | x |
| 2009-12-31 | $1.79 | $2.67 | x |
| 2010-12-31 | $1.87 | $2.67 | x |
| 2011-12-31 | $2.11 | $2.67 | x |
| 2012-12-31 | $2.13 | $2.67 | x |
| 2013-12-31 | $2.31 | $2.67 | x |
| 2014-12-31 | $2.39 | $2.67 | x |
| 2015-12-31 | $2.16 | $2.67 | x |
| 2016-12-31 | $2.85 | $2.67 | x |
| 2017-12-31 | $3.35 | $2.67 | x |
| 2018-12-31 | $3.39 | $2.67 | x |
| 2019-12-31 | $3.04 | $2.67 | x |
| 2020-12-31 | $2.27 | $2.67 | x |
| 2021-12-31 | $2.21 | $2.67 | x |
| 2022-12-31 | $1.91 | $2.67 | x |
| 2023-12-31 | $1.16 | $2.67 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Psychemedics Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -62.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -18.80%
- • Asset Turnover: 1.79x
- • Equity Multiplier: 1.85x
- Recent ROE (-62.26%) is below the historical average (-6.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1987 | -225.00% | -1800.00% | 0.10x | 1.25x | $-1.88 Million |
| 1989 | -142.86% | -333.33% | 0.27x | 1.57x | $-1.07 Million |
| 1990 | -350.00% | -123.53% | 1.13x | 2.50x | $-2.16 Million |
| 1991 | -55.56% | -60.00% | 0.76x | 1.22x | $-1.77 Million |
| 1992 | -19.23% | -12.50% | 1.33x | 1.15x | $-760.00K |
| 1993 | 28.57% | 15.15% | 1.50x | 1.26x | $650.00K |
| 1994 | 18.75% | 20.69% | 0.84x | 1.07x | $840.00K |
| 1995 | 16.84% | 15.84% | 0.99x | 1.07x | $650.00K |
| 1996 | 17.48% | 20.49% | 0.78x | 1.10x | $1.07 Million |
| 1997 | 14.97% | 16.23% | 0.81x | 1.13x | $830.00K |
| 1998 | 15.09% | 13.56% | 0.95x | 1.18x | $810.00K |
| 1999 | 19.49% | 11.73% | 1.38x | 1.20x | $1.12 Million |
| 2000 | 19.47% | 8.84% | 1.74x | 1.27x | $825.98K |
| 2001 | 3.43% | 1.48% | 1.73x | 1.35x | $-444.67K |
| 2002 | 19.79% | 7.81% | 1.99x | 1.27x | $621.33K |
| 2003 | 23.84% | 7.62% | 2.20x | 1.42x | $707.18K |
| 2004 | 44.33% | 14.59% | 2.25x | 1.35x | $2.14 Million |
| 2005 | 45.52% | 18.93% | 1.92x | 1.25x | $3.16 Million |
| 2006 | 42.61% | 20.93% | 1.77x | 1.15x | $3.75 Million |
| 2007 | 32.31% | 18.25% | 1.58x | 1.12x | $3.10 Million |
| 2008 | 28.11% | 12.94% | 1.82x | 1.20x | $1.91 Million |
| 2009 | 16.43% | 9.01% | 1.60x | 1.14x | $597.86K |
| 2010 | 26.81% | 13.00% | 1.71x | 1.21x | $1.64 Million |
| 2011 | 31.62% | 14.48% | 1.75x | 1.25x | $2.39 Million |
| 2012 | 26.55% | 11.81% | 1.79x | 1.26x | $1.86 Million |
| 2013 | 30.99% | 14.16% | 1.62x | 1.35x | $2.58 Million |
| 2014 | 24.98% | 10.98% | 1.21x | 1.88x | $1.92 Million |
| 2015 | 12.95% | 5.60% | 1.21x | 1.92x | $343.82K |
| 2016 | 42.79% | 17.13% | 1.56x | 1.60x | $5.12 Million |
| 2017 | 32.87% | 15.42% | 1.50x | 1.42x | $4.26 Million |
| 2018 | 24.45% | 10.74% | 1.71x | 1.33x | $2.71 Million |
| 2019 | 9.17% | 4.09% | 1.37x | 1.64x | $-140.00K |
| 2020 | -30.84% | -18.07% | 0.89x | 1.92x | $-5.11 Million |
| 2021 | -5.43% | -2.67% | 1.16x | 1.76x | $-1.89 Million |
| 2022 | -10.06% | -4.29% | 1.35x | 1.74x | $-2.16 Million |
| 2023 | -62.26% | -18.80% | 1.79x | 1.85x | $-4.82 Million |
Industry Comparison
This section compares Psychemedics Corporation's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Psychemedics Corporation (PMD) | $5.45 Million | -225.00% | 0.81x | $11.49 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |